The Impact of Protracted Withdrawal Symptoms on the Compliance of Naltrexone
范书欣,宋森林,连智,李晓东,卓福镇,何荣昌,许望纯,李龙辉,孙桂宽,刘锐克,刘志民
DOI: https://doi.org/10.3969/j.issn.1006-902x.2008.01.002
2008-01-01
Abstract:Objective: To discuss the impact of protracted withdrawal symptoms (PWS) on the compliance of naltrexone and the relativity of these. Methods: Evaluation on the relativity of PWS and compliance of naltrexone for heroin addicts ,which are taking or have taken naltrexone, by multi-center retrospect epidemiological survey. Depending on the time of naltrexone maintenance, all these heroin addicts are divided into three groups, which are short-term group (≤4 weeks), long-term group (≥24 weeks) and medium group (4 weeks and 4 weeks).The scale of PWS and information about naltrexone maintenance are the main data. Results: By F-test , there are significant differences in the sum and totally 7 items of the scale, which are parts of three groups, disorder of sleep, somatic symptoms and anxiety respectively(P0.05). Based on the further P-test among groups, there are significant differences in the sum and 4 items of PWS scale, including easy to wake up, early morning awakening, systemic fatigue and suffering, between short-term and medium group(P0.05). And the sum and 4 items between short-term and long-term group , including easy to wake up, insomnia, systemic fatigue and dysphoria(P0.05). But there is no difference between medium and long-term group. The status of PWS is a negative factor on compliance of naltrexone with low relativity. By short-medium-long-term relativity analysis, there are significant relativity on the sum and 4 items (insomnia, easy to wake up, dysphoria and systemic fatigue)(P0.05). By short-medium-term relativity analysis, there are significant relativity on the sum and 6 items of PWS scale (insomnia, easy to wake up, early morning awakening, systemic fatigue and suffering and dysphoria)(P0.05). Conclusion: The status of PWS is a negative factor towards the compliance of naltrexone and plays a key role during the early period of naltrexone maintenance therapy. With PWS be well treated, the compliance of naltrexone will be enhanced/improved, so will the anti-relapse efficacy of naltrexone prevention and intervention.